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Neonatal umbilical cord blood 
transplantation halts skeletal 
disease progression in the murine 
model of MPS-I
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Umbilical cord blood (UCB) is a promising source of stem cells to use in early haematopoietic stem 
cell transplantation (HSCT) approaches for several genetic diseases that can be diagnosed at birth. 
Mucopolysaccharidosis type I (MPS-I) is a progressive multi-system disorder caused by deficiency 
of lysosomal enzyme α-L-iduronidase, and patients treated with allogeneic HSCT at the onset 
have improved outcome, suggesting to administer such therapy as early as possible. Given that 
the best characterized MPS-I murine model is an immunocompetent mouse, we here developed a 
transplantation system based on murine UCB. With the final aim of testing the therapeutic efficacy 
of UCB in MPS-I mice transplanted at birth, we first defined the features of murine UCB cells and 
demonstrated that they are capable of multi-lineage haematopoietic repopulation of myeloablated 
adult mice similarly to bone marrow cells. We then assessed the effectiveness of murine UCB cells 
transplantation in busulfan-conditioned newborn MPS-I mice. Twenty weeks after treatment, 
iduronidase activity was increased in visceral organs of MPS-I animals, glycosaminoglycans storage was 
reduced, and skeletal phenotype was ameliorated. This study explores a potential therapy for MPS-I at 
a very early stage in life and represents a novel model to test UCB-based transplantation approaches for 
various diseases.
Haematopoietic stem cell transplantation (HSCT) can cure or greatly ameliorate a wide variety of genetic dis-
eases, including defects of haematopoietic cell production or function and metabolic diseases mainly affecting 
solid organs1. In post-natal life, haematopoietic stem cells (HSCs) reside in the bone marrow (BM), so this was 
historically the first source of cells employed for HSCT. However, immediately after birth, HSCs can still be found 
in the fetal blood that flows in the umbilical cord vessels (umbilical cord blood, UCB). Unrelated donor UCB has 
several potential advantages over BM for HSCT, since it offers a relative ease of procurement, a greater degree of 
HLA (humal leukocyte antigen)-mismatch, with increased probability to find a suitable donor and lower incidence 
of acute and chronic graft versus host disease (GVHD), and reduced risk of viral infections (like Epstein-Barr 
virus and Cytomegalovirus)1–4. Furthermore, in the specific case of transplantation for inborn errors of metab-
olism (IEMs), UCB transplantation (UCBT) shows two significant extra-advantages over BM transplantation 
(BMT)3, 5–7. First, the availability of cells to transplant is more rapid, thanks to the augmented probability to find 
HLA-matched donors and the existence of cord blood banks where UCB units are stored frozen and ready to use. 
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This factor is of primary importance because in many IEMs the timing of the treatment has a strong impact on 
patient outcome. Additionally, more patients transplanted with UCB achieve full donor chimerism and thus can 
obtain a normalization of the deficient enzyme levels in biological fluids, with consequent clinical benefits3, 6, 8.
New strategies and novel developments are expected to improve engraftment and reconstitution, and to ena-
ble in utero or neonatal UCB-based transplantation for early therapy of these diseases2, 9. Thus, convenient small 
animal models of these disorders are essential to investigate these developing strategies in the field of HSCT, 
including the use of alternative cellular sources and/or genetically modified HSCs.
Even though immunodeficient mouse models of many genetic disorders are available, in which the transplan-
tation of human HSCs is feasible, many diseases lack an immunocompromised model that could fully recapitulate 
their clinical manifestations. In the case of Mucopolysaccharidosis type I-Hurler syndrome (MPS-IH), a lysoso-
mal storage disease due to mutations in the α-L-iduronidase (IDUA) gene, immunocompetent mouse models 
have been deeply characterized for several features typical of this complicated disorder10–13. Recently, MPS-I 
immunocompromised models have been generated, but some aspects representative of the disease are not com-
pletely investigated yet14, 15. In this disorder, the absence of IDUA activity causes the progressive accumulation of 
glycosaminoglycans (GAGs) in tissues, which leads to multiple organ dysfunction, with central nervous system 
involvement and various skeletal anomalies known overall as dysostosis multiplex16, 17. The current first line ther-
apy for MPS-IH is HSCT, which provides a constant reservoir of enzyme replacement through the engraftment 
of donor cells, and the use of UCB as stem cell source seems to guarantee the best results. However, transplanta-
tion is not completely effective in ameliorating bone abnormalities and neurocognitive dysfunctions, especially 
when it is performed late in childhood7, 8, 18, 19. Clinical and preclinical evidences attest that the precociousness of 
the treatment is critical to prevent long-term pathological consequences20. For this reason, we tested an UCBT 
approach at early age in MPS-I murine model10, to investigate a novel and promising therapeutic strategy. Very 
few data are present in the literature about murine UCBCs and their transplantation. Attempts to mimic UCBT 
have been made with either fetal liver cells, blood or BM collected from mouse fetuses during the last third of 
pregnancy, or newborn blood21–27, but, to our knowledge, no published data exists about the transplantation of 
murine UCB into newborn recipients, in particular in a mouse model of disease attesting a clinical correction.
Building upon the data from our previous study where we observed that the transplantion of normal BM into 
newborn MPS-I mice, soon after the placental protection, can prevent GAGs accumulation in multiple organs 
and the distinctive skeletal dysplasia28, in this study we provide an extensive description of murine UCB cells 
(UCBCs) features, in comparison with adult BM cells (BMCs). We characterized UCBCs in vitro, by flow cytome-
try and colony forming cell (CFC)-assay, and assessed the repopulating ability of UCBCs in conditioned adult and 
newborn wild-type (WT) mice. Finally, we focused on the pathological setting and investigated a novel treatment 
strategy based on the transplantation of UCBCs in MPS-I mice at birth. We extensively evaluated the outcome of 
this therapy, regarding restoration of enzyme activity, reduction of GAG deposits in plasma and visceral organs, 
and correction of the skeletal phenotype.
Results
Collection of UCBCs and their comparison with adult BMCs in vitro. We collected UCBCs at ges-
tational day E18 from C57BL/6 pregnant dams, which carried a mean number of fetuses/dam of 6.97 (standard 
deviation [SD] 1.81; n = 72 dams). The mean number of UCBCs collected from each dam was 1.38 × 106 (SD 
4.51 × 105), and it varied proportionally with the number of fetuses/dam (data not shown). The mean number of 
cells obtained from each fetus was 19.8 × 104 (SD 5.64 × 104) (Fig. 1A). Haematopoietic cells belonging to differ-
ent lymphoid and myeloid lineages were found both in UCB and adult BM, as shown in the representative flow 
cytometry panels in Fig. 1B. However, the proportion of lymphocytes (T cells and B cells) and of myeloid cells 
(monocytes/macrophages and granulocytes) was higher in BM than in UCB, suggesting that UCB could contain 
less mature cell populations (Supplementary Table S1). Interestingly, Ter119+ erythrocytes were very few in BM 
after lysis but remained at a high percentage in UCB, probably because they are mostly immature and resistant to 
hypotonic shock (Supplementary Figure S2). Regarding the HSCs subset easily detectable within adult BMCs by 
Lin−Sca-1+c-kit+ (LSK) staining, in UCBCs specimens there was a reduced proportion of LSK cells (Fig. 1B). In 
the colony-forming cell (CFC) assay, performed to investigate the functionality of the haematopoietic progeni-
tors, a similar frequency of colonies was found in UCB and BM (median 35.0 colonies/plate in UCB, range from 
16 to 112, and 39.0 colonies/plate in BM, range from 18 to 78; p = 1) (Fig. 1C). However, in UCB the majority of 
the colonies (93.2%) had a peculiar morphology, consisting of colonies containing large blast-like cells on a single 
layer (Fig. 1D,E). These cells resemble the previously defined High Proliferative Potential-Colony-Forming Cells 
(HPP-CFC), primitive multipotent progenitor cells absent in BM-derived colonies23. Excluding HPP-CFCs, the 
relative distribution of the other colony subtypes (CFU-GEMM, BFU-E, CFU-GM) did not differ between UCB 
and BM (p = 0.06, Chi-square test) (Fig. 1D). The different subtypes of UCB and BM haematopoietic colonies 
were morphologically indistinguishable (Fig. 1E).
UCB contains long-term multi-lineage repopulating haematopoietic stem cells. Before per-
forming the transplantion of UCBCs into newborn MPS-I mice, we assessed whether they were able to rescue 
lethally-conditioned adult mice, to differentiate into cells of lymphoid and myeloid lineages, to persist long-term, 
and to repopulate in serial transplants. In an initial set of experiments, lethally-irradiated adult C57BL/6-CD45.1 
mice were transplanted with 5 × 105 CD45.2+ UCBCs (adult UCBT group, aUCBT) or with the same number of 
murine adult BMCs (adult BMT group, aBMT). At 1 month after transplantation, the short-term engraftment of 
donor cells was assayed in peripheral blood (PB), BM, spleen, and thymus of the recipients, by flow cytometric 
analysis of the leukocytes marked with anti-CD45.1 and anti-CD45.2 antibodies (Fig. 2A). In the aUCBT group, 
median engraftment in PB was 71.7% (range from 66.9% to 74.3%), even higher than the one in the aBMT group 
that was 58.4% (range from 42.3% to 68.3%; p = 0.03). In the BM, the median donor chimerism was 82.5% in the 
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aUCBT group and 83.3% in the aBMT group, while it was, respectively, 62.7% and 69.3% in the spleen, and 22.8% 
and 23.2% in the thymus, without significant differences between UCBCs and BMCs (p = 1, p = 0.90, p = 0.56, 
respectively). We next assessed if it was possible to use lower doses of UCBCs (2.5 × 105 and 1 × 105 cells/mouse) 
to establish long-term, stable chimerism. Rates of engraftment (number of surviving mice with ≥1% donor cells/
total number of transplanted mice) were 100% for all the tested doses. While at 1 month after transplantation 
the level of donor cell engraftment in PB depended on the transplanted cell dose, beginning from 4 months after 
transplantation the engraftment reached values over 90% in all the experimental groups (Fig. 2B). More impor-
tantly, UCBCs showed long-term repopulation ability, since PB engraftment was maintained up to 12 months 
after aUCBT. The engraftment in other haematopoietic organs was assayed at 4 months after transplantation, and 
it reached a median of 98.2% in BM, 93.5% in spleen, and 92.1% in thymus (data not shown). The presence of cells 
arisen from the original UCBCs (CD45.2+ cells) in both lymphoid (T and B cells) and myeloid (monocytes/mac-
rophages and granulocytes) lineages was attested in BM, spleen and thymus by flow cytometry (Fig. 2C). CD45.2+ 
LSK cells were also found in the BM of recipient mice, suggesting that, even if LSK cells were detected as a very 
rare population in UCB, UCBCs were able to repopulate also the HSCs pool in the recipients’ BM (Fig. 2C). To 
evaluate the functionality of UCB-derived haematopoietic progenitors, CD45.2+ cells were sorted 4 months after 
aUCBT from the BM of recipients and were tested in a CFC-assay, showing the differentiation in colonies belong-
ing to all the different subtypes (Fig. 2D,E). Finally, a secondary transplantation assay into lethally-irradiated 
CD45.1 recipients was performed, to verify whether UCBCs contained long-term HSCs. The presence of sus-
tained and durable levels of PB engraftment in secondary mice confirmed self-renewal and long-term repopula-
tion capability of UCB-derived HSCs (Fig. 2F). CD45.2+ mature subpopulations and LSK cells were also present 
in BM of secondary mice (data not shown).
Transplantation of UCBCs in the neonatal setting. For the transplantation of newborn mice, we 
adopted a previously established protocol with few modifications28. After conditioning with busulfan, CD45.2 
newborn mice were intravenously transplanted with either CD45.1+ UCBCs (neonatal UCBT group, nUCBT) 
Figure 1. Murine UCBCs have unique features compared with BMCs. (A) Number of UCBCs obtained at day 
E18 from each fetus (n = 502 fetuses). The distribution of the medium number of cells per fetus was represented 
by density histogram with Gaussian approximation. (B) Representative flow cytometry analysis of UCB and BM 
haematopoietic subpopulations: T cells (CD45+CD3+), B cells (CD45+B220+), myeloid cells (CD45+Mac-1+ 
and CD45+Gr-1+), erythroid cells (TER-119+), and LSK cells (lin-Sca-1+c-Kit+). Percentages of lymphocytes 
and myeloid cells were referred to CD45+ leukocytes, percentage of Ter119+ was referred to all cells (after 
hypertonic treatment), and percentage of LSK cells was referred to Lin- leukocytes. (C) Absolute number of 
haematopoietic colonies detected on methylcellulose at day 14 after plating 2 × 104 UCB or BM cells/petri 
(n = 11 UCB, n = 6 BM). Data are represented by boxplot graphs, showing the exact data values by black dots. 
P = 1 with 2-sided Wilcoxon unpaired test. (D) Barplot with percentage of the different subtypes of HPP-CFC, 
CFU-GEMM, BFU-E and CFU-GM (CFU-M, CFU-G, and CFU-GM) among the total number of colonies 
obtained from UCB or BM. (E) Representative photographs of the different subtypes of haematopoietic colonies 
in UCB and BM (10X magnification, bar: 400 μm) and of their cytospin preparations stained with May-
Grumwald Giemsa (200X magnification, bar: 200 μm). CFU-GEMM = Colony-Forming Unit-Granulocyte, 
Erythroid, Macrophage, Megakaryocyte; BFU-E = Burst-Forming Unit-Erythroid; CFU-M = Colony-Forming 
Unit-Macrophage; CFU-G = Colony-Forming Unit-Granulocyte; CFU-GM = Colony-Forming Unit-
Granulocyte, Macrophage; HPP-CFC = High Proliferative Potential-Colony-Forming Cell.
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or adult BMCs (neonatal BMT group, nBMT). The cell dose we defined to transplant (2 × 105 cells/mouse) was 
ideally comparable with the mean number of UCBCs harvested from a single fetus. At 1 month after transplanta-
tion, no difference in the PB engraftment was observed between nUCBT group (median: 18.5%, range from 1.0% 
to 71.8%) and nBMT group (median: 30.5%, range from 2.6% to 66.1%; p = 0.10, including in our analysis only 
successfully transplanted mice with donor chimerism ≥1%) (Fig. 3A). nUCBT mice with PB engraftment ≥50% 
at 1 month were analyzed serially at 2 and 4 months, and the levels of engraftment in PB increased over time, 
approaching full donor chimerism (Fig. 3B). The engraftment in BM, spleen, and thymus, the differentiation of 
transplanted UCBCs in lymphoid and myeloid lineages, and the retention of LSK cells were evaluated at 6 months 
post transplantation, and the results were comparable with the ones obtained in aUCBT mice (Supplementary 
Figure S1 and data not shown). Thus, we could also confirm in the neonatal setting the haematopoietic repopu-
lation ability of UCBCs.
Figure 2. Murine UCBCs demonstrate long-term multi-lineage haematopoietic repopulating activity in adult 
transplantation setting. (A) Levels of donor chimerism [donor CD45 cells/(donor + host CD45 cells) × 100] 
were determined by flow cytometry in the haematopoietic organs of adult lethally-irradiated recipients at 1 
month after the transplantation of 5 × 105 UCBCs (aUCBT) or BMCs (aBMT) (n = 4 aUCBT, n = 5 aBMT). 
*p ≤ 0.05 by Wilcoxon test. (B) Levels of chimerism analyzed serially in the PB of recipient mice between 
1 and 12 months after the transplantation of 5 × 105, 2.5 × 105, or 1 × 105 UCBCs/mouse (each line in the 
plot represents a single mouse). (C) Representative lineage distribution of UCB-derived cells in the BM, 
spleen, and thymus of recipient mice at 4 months after aUCBT. Dot plots to determine donor-derived T cells 
(CD45.2+CD3+), B cells (CD45.2+B220+), myeloid cells (CD45.2+Mac-1+ and CD45.2+Gr-1+), and LSK cells 
(CD45.2+lineage-Sca-1+c-Kit+) are shown. (D) FACS sorting of CD45.2+ UCB-derived cells from the BM of 
a primary aUCBT recipient at 4 months after transplantation. (E) Representative photographs and count of 
the different subtypes of haematopoietic colonies on methylcellulose formed by UCB-derived (CD45.2+) BM 
sorted cells (10X magnification, bar: 400 μm). (F) Donor chimerism in the PB of secondary mice after the 
transplantation of 3 × 106 UCB-derived (CD45.2+) BM sorted cells (n = 3 recipient mice). Each black dot in the 
plot represents a single mouse, analyzed at 1, 2, and 4 months after transplant.
www.nature.com/scientificreports/
5SCIenTIfIC REPORTS | 7: 9473  | DOI:10.1038/s41598-017-09958-9
Engraftment and biochemical features of MPS-I mice receiving nUCBT. To investigate whether 
nUCBT could represent a curative treatment for metabolic diseases, we applied the settled protocol to the 
MPS-I mouse model. Newborn MPS-I and WT mice were transplanted with healthy UCBCs and evaluated at 
20 weeks of age for their PB engraftment, IDUA activity in organs, GAGs accumulation in organs and plasma, 
and skeletal phenotype. PB engraftment did not differ between MPS-I and WT mice at the time of sacrifice 
(median 38.7% in MPS-I, range from 1.6% to 96.2%; 9.8% in WT, range from 1.0% to 94.8%; p = 0.24) (Fig. 4A). 
Among MPS-I nUCBT mice, 5 of 12 mice presented a high haematopoietic chimerism, defined as more than 
50% donor CD45.1+ cells in PB at 20 weeks after nUCBT (median engraftment: 93.3%, range from 55.7% to 
96.2%). Hence, we included this subgroup of highly engrafted mice (named MPS-I nUCBT-hi) in all the studies 
reported hereafter. Five of 12 mice, instead, had a low haematopoietic chimerism, defined as less than 10% donor 
CD45.1+ cells in PB at 20 weeks after nUCBT, and were grouped as low engrafted mice (MPS-I nUCBT-lo). 
IDUA activity was evaluated in the spleen, liver, lung, kidney, and heart of MPS-I nUCBT mice compared with 
age-matched untreated WT and MPS-I mice. IDUA activity, which is absent in MPS-I mice and not restored in 
MPS-I nUCBT-lo mice, was partially increased in MPS-I nUCBT-hi mice in all the tissues analyzed, particularly 
in spleen, where the average values in MPS-I nUCBT-hi mice reached 40% of average WT values (Fig. 4B). In 
the same harvested tissues, we quantified GAG levels, showing that MPS-I nUCBT-hi animals displayed a statis-
tically significant reduction in GAGs storage material in all organs, in comparison with untreated MPS-I mice 
(p ≤ 0.03 for all organs) (Fig. 4C). The average reduction on MPS-I is over 50% for spleen, heart, lung and kidney. 
In particular, in spleen, liver, and lung of MPS-I nUCBThi animals GAG levels completely normalized (MPS-I 
nUCBThi vs. WT, p = 0.76, p = 1, and p = 0.11, respectively) (Fig. 4C). To further confirm the occurred correc-
tion, we measured the levels of plasma GAGs (HS-0S, HS-NS, DS, and mono-sulfated KS), showing that the levels 
of these GAGs were significantly reduced in MPS-I nUCBT-hi compared to untreated MPS-I mice (Fig. 4D). Of 
note, in MPS-I nUCBT-hi mice the level of mono-sulfated KS, which has been associated with severity of skeletal 
dysplasia in the mouse model of MPS-I, was similar to WT animals (MPS-I nUCBThi vs. WT; p = 0.72) (Fig. 4D). 
Instead, GAG levels in both peripheral organs and plasma were not consistently reduced in MPS-I nUCBT-lo 
mice (Fig. 4C,D). Taken together, these biochemical data prove that nUCBT greatly corrects the error of metabo-
lism in these tissues in animals with high donor chimerism.
Prevention of dysostosis in MPS-I mice receiving nUCBT. Dysostosis multiplex is the well-known 
skeletal consequence of MPS-I in humans and mouse models. In particular, the MPS-I model adopted in this 
work shows abnormal craniofacial bone morphology and progressive thickening of the long bone segments. At 
the age of sacrifice (20 weeks) radiographic analyses confirmed a marked increase in the width of the skull and of 
the zygomatic arches in untreated MPS-I mice compared to WT animals (Fig. 5A). Instead, in MPS-I nUCBT-hi 
mice, a significant reduction of these parameters was observed (skull width p = 0.008; zygomatic arch width 
p = 0.005, MPS-I nUCBT-hi vs. untreated MPS-I mice).
A similar trend was observed in the femur and humerus, where the thickening and the meta-diaphyseal scle-
rosis of the skeletal bones of MPS-I mice revealed by radiographic analysis were prevented in MPS-I nUCBT-hi 
animals (Fig. 5B).
Considering that busulfan toxicity per se could cause a reduction in bone dimensions of treated mice regardless 
of their genotype, we adopted a regression model capable of separating the adverse effect of busulfan treatment from 
the therapeutic effect of transplantation on MPS-I28. By this analysis, we obtained the confirmation of the differ-
ential effect of the treatment on MPS-I attributable to transplantation only (Supplementary Table S2). Moreover, 
Figure 3. Murine UCBCs confirm long-term multi-lineage haematopoietic repopulating activity in neonatal 
transplantation setting. (A) Levels of donor chimerism were determined by flow cytometry in the PB of 
busulfan-conditioned newborn mice at 1 month following the transplantation of 2 × 105 UCBCs (nUCBT) or 
BMCs (nBMT) cells (n = 68 nUCBT, n = 28 nBMT; p = 0.10 by Wilcoxon test). (B) Serial analysis of donor 
chimerism in the PB of nUCBT recipient mice performed at 1, 2, and 4 months after transplant (n = 10, each 
line in the graph represents a single mouse).
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considering the MPS-I nUCBT-lo group, the improvement in radiographic measurements was limited compared to 
MPS-I nUCBT-hi, confirming the importance of high donor chimerism for disease correction (Fig. 5A and B).
Micro-computed tomography (micro-CT) scans and histomorphometry performed on the femurs of male 
mice again highlighted the improvement of the skeletal phenotype in the MPS-I nUCBT-hi group. 2- and 3D 
micro-CT images revealed that the endocortical perimeter of MPS-I femurs appeared distinctly irregular at 20 
weeks and returned to normal in MPS-I nUCBT-hi mice (Fig. 6A). Specifically, all the examined parameters (total 
Figure 4. Neonatal UCBT prevents GAGs accumulation in MPS-I mice. (A) Donor chimerism (percentage 
of CD45.1+ cells) determined by flow cytometry in the PB of recipient MPS-I and WT mice at 20 weeks (time 
of sacrifice) after nUCBT (n = 12 for MPS-I, n = 12 for WT; p = 0.24 by Wilcoxon test). Dashed line indicates 
the level of 50% donor engraftment, and identifies the highly-engrafted mice group (with ≥50% donor cells in 
PB, nUCBT-hi). (B) IDUA activity in spleen, liver, lung, kidney, and heart of WT (n = 8), MPS-I (n = 8), MPS-I 
nUCBT-hi (n = 5), and MPS-I nUCBT-lo mice (n = 5). (C) GAG levels in the indicated organs of the same WT, 
MPS-I, MPS-I nUCBT-hi, and MPS-I nUCBT-lo mice. (D) Levels of ΔDiHS-0S, ΔDiHS-NS, ΔDi-4S, and 
mono-sulfated KS in the plasma of the mice. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 by Wilcoxon test.
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cortical area, cortical bone area, medullary area, and cortical thickness) were ameliorated in MPS-I nUCBT-hi 
mice, demonstrating the impact of the high donor engraftment on femoral architecture (Fig. 6B). In addition, 
comparative histomorphometric analysis of the femur cortical thickness at mid-diaphysis and the area of the 
osteocytic lacunae confirmed the benefit of nUCBT on bone abnormalities in MPS-I mice (Fig. 6C and data not 
shown).
Considering the impact that osteoclastogenesis seems to have on MPS-I disease29, we determined the effect of 
nUCBT on osteoclast numbers and function. There were no significant differences in the ability of BM cells derived 
from untreated WT and MPS-I mice to differentiate into TRAP-positive multinucleated osteoclasts ex vivo and in 
their resorptive capacity in vitro when cultured on dentine slides (Fig. 6D). Nonetheless, nUCBT treatment caused 
increased osteoclastogenesis regardless of the mice’s genotype (p ≤ 0.05, treated vs. untreated mice) (Fig. 6E), 
although an effective reduction of bone mineral density could not be found in vivo (Supplementary Figure S3).
Discussion
UCB is a clinically useful reservoir of HSCs and progenitor cells for the treatment of a wide variety of genetic 
diseases, particularly attractive for transplantation of infants and small children.
To fully realize the therapeutic potential of UCBT early after birth, it is fundamental to develop novel tools to 
test its efficacy in different defects. MPS-I offers an ideal model, since the relevance of UCBT in the treatment of 
this condition is well-known in clinic.
In this study, we demonstrate that the transplantation of murine UCBCs into lethally-irradiated congenic 
recipients long-term reconstitutes all blood cell lineages. Moreover, the BM of recipients contains cells capable of 
reconstituting the haematopoietic system of secondary hosts.
Furthermore, in the neonatal setting, MPS-I mice transplanted with UCBCs show high levels of chimerism 
with the donor healthy cells, that are both well tolerated and therapeutic. Indeed, the long-term engraftment 
Figure 5. Neonatal UCBT prevents bone thickening in MPS-I mice. (A) On the left, representative radiographs 
of the skull of 20-weeks-old WT, MPS-I, WT nUCBT, MPS-I nUCBT-hi, and MPS-I nUCBT-lo mice. On 
the right, measurements of the skull width and zygomous width, performed on radiographs of WT (n = 6, 3 
males and 3 females), MPS-I (n = 6, 3 males and 3 females), WT nUCBT (n = 7, 3 males and 4 females), MPS-I 
nUCBT-hi (n = 5, 3 males and 2 females), and MPS-I nUCBT-lo mice (n = 5, 3 males and 2 females). (B) On 
the left, representative radiographs of the femur of 20-weeks-old WT, MPS-I, WT nUCBT, MPS-I nUCBT-hi, 
and MPS-I nUCBT-lo mice. The increase in meta-diaphyseal bone density observed in MPS-I (asterisks) is 
significantly prevented in MPS-I nUCBT-hi mice. On the right, measurements of the femur and humerus 
widths, performed on the radiographs of the same animals as in panel A. *p ≤ 0.05, **p ≤ 0.01, by Wilcoxon 
test.
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results in the partial restoration of IDUA enzyme activity, clearance of GAGs storage, and significant improve-
ment in altered bone architecture, with prevention of the skeletal phenotype.
In contrast to adult murine BM, the features of murine UCB have been poorly investigated. In a few studies, 
blood from late fetal and newborn mice has been employed, due to the similar hallmarks with UCB obtained 
at birth in human beings. In the current study, we used UCB collected from murine fetuses at embryonic day 
18. Even if UCB contained few nucleated cells, the collected cell population comprised the most representative 
committed lineages (T cells, B cells, and myeloid cells), although in different proportions if compared to BMCs. 
Notably, the majority of T cells are immature, with a double positive CD4+CD8+ phenotype and low levels of 
TCRα/β, as similarly reported for human UCB27, 30. Both the low percentage of mature T cells and the weak 
reactivity of the numerous immature T cells can be responsible for the reduced incidence of GVHD in patients 
transplanted with UCB31. The almost complete absence of mature lymphocytes and the reduced number of innate 
immunity cells are allowed by the intra-uterine protection during fetal life32. Differently from murine adult BM, 
murine UCB is characterized by the presence of Ter119+ immature red blood cells resistent to hypotonic shock, 
Figure 6. Neonatal UCBT improves cortical bone architecture in MPS-I mice. (A) Representative 2D and 3D 
micro-CT images showing regions of femoral cortical bone in WT, MPS-I, and MPS-I nUCBT-hi 20-weeks-
old male mice. (B) Graphs representing the measurement of total area (TA/mm2), bone area (BA/mm2), 
medullary area (MA/mm2), and cortical thickness (Ct.Th/mm) of 3 mice per group (WT, MPS-I, and MPS-I 
nUCBT-hi). (C) Representative haematoxylin and eosin stained histological sections of the femur cortical bone 
at the mid-diaphysis are shown in the panels on the left. The graph illustrates the measurement (mean ± SD) of 
the area of the osteocytic lacunae within the femur cortical bone of 3 mice per group (WT, MPS-I, and MPS-I 
nUCBT-hi). The BM cavity is indicated by an asterisk. Bar: 100 μm. (D) Representative pictures of TRAP-
positive multinucleated osteoclasts differentiated ex vivo (on the left, magnification 10X; bar: 300 μm) and their 
resorption plots on dentin slices (on the right, magnification 20X). Quantification of number and resorptive 
capacity of osteoclasts obtained by ex vivo differentiation of BM cells arisen from untreated WT and MPS-I mice 
(n = 3 male mice per group). (E) Fold increase of the number and resorptive capacity of the osteoclasts obtained 
from treated mice, relative to control (untreated mice of the respective genotype) (mean ± SD). *p ≤ 0.05 by 
Wilcoxon test.
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including a population of nucleated red blood cells. These data are consistent with similar results reported for 
human UCB, which contains two distinct red cells populations, a minority of rapidly lysed cells and a majority of 
slowly disrupted cells33.
Regarding the HSCs subset, the proportion of LSK cells, easily detectable within adult BM, was very low in 
UCB. This is consistent with the findings of Migishima et al., who stated that murine UCB virtually lacked cells 
with the LSK phenotype representative of adult BM-derived HSCs24. Considering that UCB cells successfully 
reconstituted lethally irradiated recipients, the authors conclude that some phenotypic differences between BM 
and UCB HSCs may exist. A possibility is that UCB HSCs do not express Sca-1, since they found a population 
of Lin−c-Kit+ cells among the side population. Another possibility is that UCB HSCs express Mac-1 similarly to 
fetal liver HSCs, and consequently a LSK phenotype can be observed only if the anti-Mac-1 antibody is removed 
from the anti-lineage cocktail34, 35.
Furthermore, the majority of the colony progenitors was constituted by multipotent precursors that give rise 
to colonies with a peculiar blast-like morphology when cultured in vitro, resembling the previously-defined 
HPP-CFC23. As already reported, this population of haematopoietic cells demonstrating HPP-CFC activity begins 
to be present in the yolk sac and in the embryo and represents the earliest multi-potential precursors within the 
haematopoietic hierarchy than can be cultured without stromal support36. Similarly, human UCB cultures contain 
a higher proportion of immature, late developing, multi-potential colony-forming cells than adult BM cultures37.
Even though these findings indicate that UCB has a different composition compared to BM, UCBCs can 
engraft with an extent similar to adult BM. In the congenic context, we do not observe any post-transplantation 
delay in haematopoietic recovery, differently than previously reported by Li et al. in an allogeneic UCBT model26. 
Notably, the persistence of donor-derived lymphoid and myeloid lineages over 4 month after transplantation 
demonstrates the long-term function of the HSCs contained in UCB, considering that most precursors and 
short-term HSCs that repopulate soon after transplantation are short-lived and disappear within 3 to 4 months 
after transplant in mice38. It has been further demonstrated that T and B cells derived from UCB-HSCs are fully 
competent in immunological terms25. Long-term repopulating function of HSCs in UCB was definitively con-
firmed by the robust contribution to multi-lineage engraftment in secondary irradiated recipients. Thus, HSCs 
from late fetal blood have a long-term multi-lineage repopulating ability similar to those in adult BM, in agree-
ment with the similar competitive repopulation capacity previously demonstrated by Harrison et al.22.
Using a myelo-ablative conditioning regimen based on busulfan described in our previous work28, we could 
demonstrate that also in the neonatal setting UCB has been able to repopulate the haematopoietic tissues, show-
ing long-term multi-lineage reconstitution in mice transplanted at birth. Moreover, we showed that the number 
of cells derived from a single UCB sample can provide sufficient long-term repopulating ability to fully maintain 
a newborn recipient for at least 20 weeks.
To our knowledge, these are the first in vivo experiments carried out using UCBCs to perform a transplant at 
neonatal age. This new model of UCBT offers a potential tool to elucidate the biological features of the perinatal 
haematopoietic stem/progenitor cells and to develop early UCB-based therapies.
Notably, allogeneic murine late fetal or newborn blood has been transplanted in adult mouse models for pre-
vention or treatment of autoimmune diseases such as type I diabetes and systemic lupus erythematosus39, 40, but 
never in models of genetic disorders at birth.
In Hurler disease, UCB has become in the most recent years the preferential stem cell source for affected 
infants and children because, in comparison with BM, this source demonstrated more immediate availabil-
ity, higher donor chimerism, better enzyme recovery in blood, and superior engrafted-and-alive rates8. In our 
study, we provide evidence that neonatal UCBT in MPS-I mice allows efficient and long-term haematopoietic 
engraftment. Twenty weeks after neonatal UCBT, MPS-I mice with more than 50% replacement by donor-derived 
haematopoiesis demonstrated near-complete normal values of biochemical parameters in visceral organs as com-
pared with affected control mice. Indeed, the level of GAGs, which is an indicator of the disease progression, in 
the majority of the tissues investigated was completely normalized, confirming the efficacy of an early approach 
based on the infusion of UCBCs. Notably, the keratan sulfate (KS) level, which could be considered a biomarker 
of skeletal dysplasia in MPSs41, 42, was normalized after neonatal UCBT in MPS-I mice. We then focused our stud-
ies on skeletal disease, considering that it is one of the unmet clinical needs of utmost importance in transplanted 
MPS-I patients.
Definitely, the reconstitution of normal haematopoiesis in MPS-I mice was associated with a consistent 
amelioration of bone pathology, as revealed by radiographic skeletal examination. Micro-CT scans and histo-
morphometry remarked the impact of the high donor engraftment on the internal architecture of the femurs of 
transplanted mice. This could be due to enzyme delivery by haematopoietic cells close to the bone and also to 
tissue reconstitution by other donor-derived multipotent stem cells. Indeed, we recently demonstrated that a rare 
population of cells within the non-haematopoietic fraction of UCB, named cord blood-borne fibroblasts, shows 
in vitro and in vivo chondrogenic ability and the specific capacity of generating in vivo bone and a BM stroma that 
supports functional haematopoiesis43, 44. Furthermore, Uchida et al. demonstrated that murine UCB transplanta-
tion could fully reconstruct not only haematopoietic cells, but also mesenchymal cell lineages able to differentiate 
into osteoblastic cells in response to environmental specific cues45, 46.
Using a statistical model that separates the therapeutic effects of UCBT on MPS-I bones from the toxic effect 
of busulfan treatment on bones of transplanted MPS-I or WT mice28, we could definitively demonstrate that neo-
natal UCBT reduced bone thickening in the skull, zygomatic arches, and long bone segments.
Another reported side-effect of the conditioning regimens with cyto-reductive chemotherapy agent such as 
busulfan is bone loss due to increased bone resorption47. In this sense, we observed a significant increase in the 
capacity of BM cells obtained from transplanted MPS-I mice to differentiate in TRAP-positive multinucleated 
osteoclasts ex vivo, but without achieving any actual reduction of femoral bone mineral density in vivo. A further 
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assessment of bone turnover markers could be important to better elucidate the effect of conditioning on bone 
metabolism of MPS-I, in which the RANKL/OPG system is already altered48.
UCB represents a promising source of stem cells for early HSCT therapeutic approaches for several diseases 
that can be diagnosed at birth and has several advantages such as easy and quick procurement, absence of risk to 
donors, immediate availability, low risk of transmitting infections, greater tolerance of HLA disparity, and lower 
incidence of severe GVHD1, 2, 4. Furthermore, UCB has unique composition and biological characteristics, due to 
the presence of HSCs as well as a mixture of multipotent stem cells such as unrestricted somatic stem cells, mes-
enchymal stem cells, and endothelial colony-forming cells able to regenerate numerous tissue types with func-
tional improvements3, 49. For example, the administration of human UCB cells into MPS-III B mice decreased 
behavioral abnormalities and tissue pathology50. In particular, the neuroprotective effect of human UCBCs seems 
to be a function of enzyme delivery and anti-inflammatory effect mediated by donor cells found throughout the 
brain and can be enhanced by repeated administrations51. We do not know whether neonatal UCBT could be also 
effective at preventing or reverting brain pathology in MPS-I disease. Although not investigated in our work, it is 
an important outstanding question that should be addressed in further studies.
Of note, UCB offers an alternative source of HSCs for gene therapy approaches, considering the possibility of 
collecting and storing autologous UCB at birth and reinfusing HSCs in the affected children after gene correc-
tion procedure. UCB-derived HSCs represent a particularly favorable target for gene therapy, given the reported 
high gene transfer rates52. Moreover, a neonatal gene therapy approach could help to achieve supra-normal 
enzyme activity in transplanted mice before disease manifestation, even in the case of low levels of chimerism. 
Interestingly, a pioneering study published by Simonaro et al. showed evidence of transduction of haematopoietic 
neonatal blood stem cells derived from MPS-VI cats and long-term persistence of retrovirally transduced cells 
into adult recipients53. Further studies would be needed to identify the best preparatory regimen suitable for 
transplanting affected neonates or infants54.
In conclusion, we demonstrated in an MPS-I mouse model the advantage of combining two factors that may 
allow for a better outcome in MPS-I patients: (1) early timing of the transplant and (2) the use of UCB, which is 
considered at the moment the best HSC source for this disease. This study serves as a proof of concept to develop 
early UCB transplantation strategies for newborns affected by genetic disorders, as well as an investigational plat-
form for novel cell and gene therapy approaches for the treatment of genetic disorders diagnosed in the neonatal 
period.
Materials and Methods
Animals. C57BL/6-CD45.2 and C57BL/6-CD45.1 mice were purchased from Charles River Laboratories 
(Calco, Italy). The MPS-I mouse model (Idua−/− mice, C57BL/6-CD45.2 background)10 was purchased from 
The Jackson Laboratory (Bar Harbor, ME); a breeding colony was established and maintained from heterozygous 
mating pairs, and genotyping was performed on tail clips or ear snips DNA, as previously described10. Procedures 
involving animal handling and care conformed to institutional guidelines, in compliance with national laws and 
policies. Animals were used in accordance with a protocol approved by the Italian Ministry of Health (permit 
number 451/2015-PR).
UCB and BM cells collection. UCBCs were collected at E18 of pregnancy from C57BL/6 pregnant dams, 
as previously described24. Briefly, pregnant females were euthanized by CO2 inhalation, the uterus was removed 
and cooled in ice-cold phosphate-buffered saline (PBS, Gibco). The fetuses were isolated, and the visceral yolk sac 
and amnion were removed. Then, the umbilical cord was cut, fetuses were transferred into warm heparinized PBS 
(10 U/mL), and blood was allowed to flow out. Fetuses were then euthanized.
BMCs were collected from the long bones of 6 to 10-weeks-old C57BL/6 mice by flushing.
UCBCs and BMCs were centrifuged at 670 g for 5 minutes, lysed using ACK (Ammonium-Chloride-Potassium) 
lysing buffer (StemCell Technologies) and counted in Bürker chamber with Turk solution.
Transplantation procedures. Adult transplantation. For transplantation in adult mice, 6 to 8-weeks-old 
C57BL/6-CD45.1 females were conditioned by lethal irradiation, administered in two doses of 4.25 Gy (tot 
8.5 Gy), using the X-ray irradiator Radgil (Gilardoni S.p.A.). CD45.2+ BMCs or UCBCs were transplanted by a 
single intravenous injection within 24 hours from conditioning.
Secondary mice. For secondary transplantation experiments, BMCs were harvested from primary mice 
at 4 months after transplantation and stained with anti-mouse CD45.2 PE antibody (clone 104, eBioscience). 
CD45.2+ BMCs were sorted using a FACSAria cell sorter (BD Biosciences) and re-transplanted into congenic 
C57BL/6-CD45.1 recipients (3 × 106 cells/mouse) as described above.
Neonatal transplantation. UCBT in newborn mice was performed adjusting the scheme established by our 
group for the neonatal transplantation of murine BM28. 1 to 3-day-old pups from the MPS-I colony (CD45.2) 
were conditioned with a single intraperitoneal injection of 20 mg/kg busulfan (Busilvex, Pierre Fabre). 24 hours 
later, pups were transplanted by temporal vein injection of CD45.1+ healthy donor-derived UCBCs (2 × 105 cells/
mouse).
FACS analysis. For flow cytometry analysis of haematopoietic subpopulations, UCBCs and BMCs were col-
lected and processed as specified above. For engraftment evaluation in transplanted mice, 50 µL of peripheral 
blood (PB) were collected in heparin by tail bleeding and lysed with ACK buffer. BM was collected by flush-
ing long bones, while splenocytes and thymocytes were collected by smashing the respective organ on a 70 µm 
cell strainer (Greiner Bio-One). Employed antibodies are listed in Supplementary Methods. Acquisition was 
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performed on the FACSCanto™ II flow cytometer and the results were analyzed by FACS Diva software (BD 
Biosciences).
The levels of donor cell engraftment have been evaluated as: [donor CD45.1+/(donor CD45.1+  + recipient 
CD45.2+) × 100], (or the opposite in the case of the transplant of CD45.1+ mice with haematopoietic cells from 
CD45.2+ donor).
Colony forming cell (CFC) assay. The CFC assay was performed in semi-solid medium supplemented 
with haematopoietic cytokines. Briefly, BMCs or UCBCs were resuspended in MethoCult GF M3434 (StemCell 
Technologies), plated in 35 mm low-adherence plastic dishes (Nunc) (20.000 cells/dish), and incubated at 37 °C 
and 5% CO2. Haematopoietic colonies were identified at day +14 by morphological observation on an inverted 
microscope. The nature of individual colonies was confirmed by picking them, cytospinning the cells on glass 
slides, and staining with May-Grünwald Giemsa.
IDUA activity assay. IDUA activity was measured fluorimetrically in organs at 20 weeks after transplanta-
tion, as previously described28, 55. See the Supplementary Methods for details.
Glycosaminoglycans quantification. GAGs were quantified in plasma and organs as described28, 56. See 
the Supplementary Methods for details.
Bone phenotyping. Radiographic images of each limb and cranium were obtained by Faxitron MX-20 
Specimen Radiography System (Faxitron X-ray Corp.) at an energy of 30 kV for 90 seconds with Eastman 
X-OMAT TL film (Eastman Kodak Co.) and processed by an automated X-ray film developer (Model M35A, 
Eastman Kodak Co.). Bone thickness was measured between the outer edges of cortical bone at the mid-diaphysis 
using ImageJ software (free from the NIH website).
Femurs from 20-weeks-old mice (n = 3 male mice/group) were scanned, using a SkyScan 1172 System (Bruker) 
with a source voltage and current of 65 kV and 153 μA, respectively. Following scanning, three-dimensional 
microstructural images were reconstructed using SkyScanNRecon software. SkyScan CT Analyzer software was 
used to calculate cortical micro-architectural parameters: cortical thickness (Ct.Th/mm), Total Area (TA/mm2), 
Bone Area (BA/mm2), and Medullary Area (MA/mm2).
Histopathology. For the evaluation of bone morphology, hind limbs were fixed in 4% formaldehyde in phos-
phate buffer, decalcified in 10% EDTA (Sigma-Aldrich), routinely processed for paraffin embedding and used for 
qualitative and quantitative histological analysis. Four μm sections were deparaffinized, rehydrated, and stained 
with haematoxylin and eosin by standard procedures. For quantitative analysis, a semiautomatic image analyzer 
(IAS 2000, Delta System, Rome, Italy) was used to calculate the cortical thickness at the mid-diaphysis of the right 
femur and the area of the osteocytic lacuna within the same region of male WT, MPS-I, and MPS-I nUCBThi 
mice (n = 3 for each group, at least 100 osteocytic lacunae/mouse).
In vitro osteoclasts differentiation. For osteoclastogenesis, mononuclear cells were isolated from the BM 
of 20-weeks-old mice as described above. Cells were plated at a density of 4 × 105 cells per well in 96 multiwell 
plates in the presence of 1 μM dexamethasone (Sigma-Aldrich), 5 ng/ml TGF-β1 (RandD Systems), 25 ng/ml 
M-CSF (Peprotech), and 100 ng/ml RANKL (Peprotech), and cultured for 10 days. Medium and factors were 
replaced every 3 days.
Osteoclasts were detected 14 days after plating by cytochemical staining for TRAP (tartrate resistant acid 
phosphatase), using Leukocyte TRAP Kit 387-A (Sigma-Aldrich) according to the manufacturer’s instructions.
To determine the resorptive activity, cells were plated onto dentin discs (IDS) that were stained 21 days later 
by toluidine blue to quantify the resorbed area.
Statistical analysis. All statistical analyses were performed using R freeware software. Continuous variables 
were contrasted between groups by the nonparametric Wilcoxon test for equality of the medians. All tests were 
two-sided with a 5% significance level, except those on the micro-CT data, area of osteocytic lacunae, osteoclast 
number, and percentage of resorbed area where a 1-sided alternative was considered. Data on the distribution of 
haematopoietic colonies subtypes were analyzed using Chi-square test. An ordinary regression model with binary 
regressors was applied to assess the impact of both disease and treatment. This enabled to separate the adverse 
effect of busulfan treatment from the therapeutic effect of UCBT on MPS-I.
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